Cationic Liposome/DNA Complexes Mediate Antitumor Immunotherapy by Promoting Immunogenic Tumor Cell Death and Dendritic Cell Activation

2020 ◽  
Vol 12 (25) ◽  
pp. 28047-28056 ◽  
Author(s):  
Xiuxiu Cong ◽  
Huimin Tian ◽  
Shuhan Liu ◽  
Kuirong Mao ◽  
Hongmei Chen ◽  
...  
Keyword(s):  
Cell Death ◽  
Dendritic Cell ◽  
Tumor Cell ◽  
Cell Activation ◽  
Cationic Liposome ◽  
Tumor Cell Death ◽  
Dendritic Cell Activation ◽  
Dna Complexes ◽  
Antitumor Immunotherapy ◽  
Immunogenic Tumor Cell

scholarly journals Immunogenic tumor cell death promotes dendritic cell migration and inhibits tumor growth via enhanced T cell immunity

iScience ◽  
2021 ◽  
Vol 24 (5) ◽  
pp. 102424
Author(s):  
Taiki Moriya ◽  
Kurumi Kitagawa ◽  
Yuuki Hayakawa ◽  
Hiroaki Hemmi ◽  
Tsuneyasu Kaisho ◽  
...  
Keyword(s):  
Cell Death ◽  
Cell Migration ◽  
Dendritic Cell ◽  
Tumor Growth ◽  
Tumor Cell ◽  
T Cell Immunity ◽  
Tumor Cell Death ◽  
Cell Immunity ◽  
Dendritic Cell Migration ◽  
Immunogenic Tumor Cell

scholarly journals Laser nanobubbles induce immunogenic cell death in breast cancer

Nanoscale ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 3644-3653
Author(s):  
Hieu T. M. Nguyen ◽  
Nitesh Katta ◽  
Jessica A. Widman ◽  
Eri Takematsu ◽  
Xu Feng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Death ◽  
Dendritic Cell ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Cell Activation ◽  
Immunogenic Cell Death ◽  
Dendritic Cell Activation

Laser nanobubbles induce dendritic cell activation in breast cancer cells.

scholarly journals Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
K. Hayashi ◽  
F. Nikolos ◽  
Y. C. Lee ◽  
A. Jain ◽  
E. Tsouko ◽  
...  
Keyword(s):  
Cell Death ◽  
Cell Activation ◽  
T Cell Response ◽  
Tumor Rejection ◽  
Prostaglandin E ◽  
Immunogenic Cell Death ◽  
Tumor Cell Death ◽  
Dendritic Cell Activation ◽  
Drug Induced ◽  
Molecular Patterns

AbstractInduction of tumor cell death is the therapeutic goal for most anticancer drugs. Yet, a mode of drug-induced cell death, known as immunogenic cell death (ICD), can propagate antitumoral immunity to augment therapeutic efficacy. Currently, the molecular hallmark of ICD features the release of damage-associated molecular patterns (DAMPs) by dying cancer cells. Here, we show that gemcitabine, a standard chemotherapy for various solid tumors, triggers hallmark immunostimualtory DAMP release (e.g., calreticulin, HSP70, and HMGB1); however, is unable to induce ICD. Mechanistic studies reveal gemcitabine concurrently triggers prostaglandin E2 release as an inhibitory DAMP to counterpoise the adjuvanticity of immunostimulatory DAMPs. Pharmacological blockade of prostaglandin E2 biosythesis favors CD103+ dendritic cell activation that primes a Tc1-polarized CD8+ T cell response to bolster tumor rejection. Herein, we postulate that an intricate balance between immunostimulatory and inhibitory DAMPs could determine the outcome of drug-induced ICD and pose COX-2/prostaglandin E2 blockade as a strategy to harness ICD.

An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation

2019 ◽  
Vol 68 (9) ◽  
pp. 1479-1492 ◽  
Author(s):  
Luciano Castiello ◽  
Alessandra Zevini ◽  
Elisabetta Vulpis ◽  
Michela Muscolini ◽  
Matteo Ferrari ◽  
...  
Keyword(s):  
Cell Death ◽  
Retinoic Acid ◽  
Dendritic Cell ◽  
Cancer Cells ◽  
Cell Activation ◽  
Human Cancer ◽  
Immunogenic Cell Death ◽  
Dendritic Cell Activation ◽  
Human Cancer Cells ◽  
Inducible Gene
Sign in / Sign up

Export Citation Format

Share Document